Correction: A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy.
Johanna PrullerIsabella HoferMassimo GanassiPhilipp HeherMichelle T MaPeter S ZammitPublished in: Cancer gene therapy (2020)
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Keyphrases